NASDAQ:ENTX Entera Bio (ENTX) Stock Price, News & Analysis $1.18 -0.04 (-3.28%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.18 0.00 (0.00%) As of 06/5/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Entera Bio Stock (NASDAQ:ENTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entera Bio alerts:Sign Up Key Stats Today's Range$1.16▼$1.2250-Day Range$1.00▼$1.3752-Week Range$0.91▼$3.22Volume60,296 shsAverage Volume83,337 shsMarket Capitalization$58.16 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingHold Company Overview Entera Bio, Inc. is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations. The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis. EB613 entered Phase 1 clinical trials to assess safety, tolerability and pharmacokinetics in healthy volunteers. In parallel, Entera Bio is advancing EB612, an oral tumor necrosis factor (TNF) antagonist, toward early‐stage clinical development for inflammatory diseases such as rheumatoid arthritis and Crohn’s disease. Since its founding in 2010, Entera Bio has established operations in Newton, Massachusetts, and research facilities in Israel, positioning the company at the intersection of North American and international biopharmaceutical innovation. Its leadership team combines expertise in peptide chemistry, clinical development, regulatory affairs and commercial strategy. Entera Bio plans to collaborate with established pharmaceutical partners to support late‐stage clinical programs and the global commercialization of its oral peptide product candidates.AI Generated. May Contain Errors. Read More Entera Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreENTX MarketRank™: Entera Bio scored higher than 56% of companies evaluated by MarketBeat, and ranked 254th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingEntera Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialEntera Bio has a consensus price target of $9.00, representing about 662.7% upside from its current price of $1.18.Amount of Analyst CoverageEntera Bio has only been the subject of 2 research reports in the past 90 days.Read more about Entera Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Entera Bio are expected to decrease in the coming year, from ($0.34) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entera Bio is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entera Bio is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntera Bio has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Entera Bio's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.41% of the float of Entera Bio has been sold short.Short Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 1.35, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entera Bio has recently decreased by 5.47%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntera Bio does not currently pay a dividend.Dividend GrowthEntera Bio does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Entera Bio this week, compared to 2 articles on an average week. Company Ownership3.4 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $26,000.00 in company stock, which represents 0.0447% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Entera Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $26,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.38% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions14.11% of the stock of Entera Bio is held by institutions.Read more about Entera Bio's insider trading history. Receive ENTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENTX Stock News HeadlinesEntera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)June 2, 2026 | theglobeandmail.comEntera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting ...May 28, 2026 | markets.businessinsider.comJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears. | Brownstone Research (Ad)Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for PresentationMay 28, 2026 | globenewswire.comEntera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide ProgramsMay 8, 2026 | globenewswire.comEntera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet TranscriptApril 20, 2026 | seekingalpha.comBriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet OpportunityApril 20, 2026 | globenewswire.comEntera Bio Ltd. to Host Virtual Webinar on Osteoporosis Treatment and EB613, Its Lead Oral Anabolic CandidateApril 14, 2026 | quiverquant.comQSee More Headlines ENTX Stock Analysis - Frequently Asked Questions How have ENTX shares performed this year? Entera Bio's stock was trading at $1.94 at the start of the year. Since then, ENTX shares have decreased by 39.2% and is now trading at $1.18. How were Entera Bio's earnings last quarter? Entera Bio Ltd. (NASDAQ:ENTX) issued its earnings results on Friday, May, 8th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. When did Entera Bio IPO? Entera Bio (ENTX) raised $13 million in an IPO on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00-$10.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager. Who are Entera Bio's major shareholders? Top institutional shareholders of Entera Bio include Renaissance Technologies LLC (0.96%) and Seven Fleet Capital Management LP (0.42%). Insiders that own company stock include Miranda Jayne Toledano, Sean Ellis, Geno J Germano and Haya Taitel. View institutional ownership trends. How do I buy shares of Entera Bio? Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entera Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entera Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), GE Aerospace (GE). Company Calendar Last Earnings5/08/2026Today6/06/2026Next Earnings (Estimated)8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 ENTX's financial health is in the Red zone, according to TradeSmith. ENTX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTX CIK1638097 Webwww.enterabio.com Phone(722) 532-7151FaxN/AEmployees20Year Founded2010Price Target and Rating Average Price Target for Entera Bio$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+662.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.44 million Net MarginsN/A Pretax Margin-27,235.71% Return on Equity-83.31% Return on Assets-70.83% Debt Debt-to-Equity RatioN/A Current Ratio7.93 Quick Ratio7.93 Sales & Book Value Annual Sales$40 thousand Price / Sales1,454.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book4.07Miscellaneous Outstanding Shares49,290,000Free Float44,115,000Market Cap$58.16 million OptionableOptionable Beta1.56 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:ENTX) was last updated on 6/6/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHow to get into the SpaceX IPO before June 12Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredShe called ASTS before it ran 133%. Here's the system behind it.Danielle Shay called AST SpaceMobile on Fox Business before it ran 133% - and found NBIS at $54 before it gapp...Simpler Trading | SponsoredWhy is this free?Simple Options Trading For Beginners normally sells for $29.97 - but right now Bill Poulos has opened a free w...Profits Run | Sponsored17,000 filings. One word kept appearing.After reading every 10-K filed by S-P 500 companies over 30 years - 17,000 filings, 3 million pages - one word...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
